News Medical on MSN1d
Chronic inflammation's connection to atrial fibrillation points to IL-1β as a promising treatment targetA recent Brazilian study published in Nature Cardiovascular Research has highlighted promising pathways for preventing and ...
The global atrial fibrillation drugs market size was valued at USD 24.59 billion in 2024 and is projected to reach from USD ...
Atrial fibrillation outcomes in patients from Asia and non-Asia countries: insights from GARFIELD-AF
Background Differences in the clinical outcomes and level of risk among Asian versus non-Asian patients with atrial fibrillation (AF) have been sparsely investigated.Objective To provide a ...
Discover how abelacimab reduces bleeding risks in AFib patients by effectively lowering free factor XI levels.
7don MSN
A 240-year-old drug called digoxin could save the National Health Service (NHS) at least £100 million each year when treating ...
Favorable bleeding outcomes related to abelacimab have positioned the medication as a potential game changer in the treatment of atrial fibrillation.
The atrial fibrillation (AF) device market is experiencing rapid growth, fueled by the rising prevalence of atrial fibrillation, increasing awareness of early diagnosis, and advancements in medical ...
Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback